Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Chemoradiotherapy in Stage III-IVA Cervical Cancer
NCT06419673Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Cervical Cancer (CC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2024; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06419673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419673.